Navigation Links
Prism Pharmaceuticals' Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology

- First time IV formulation of clopidogrel, the active ingredient in

PLAVIX(R), is studied in humans -

KING OF PRUSSIA, Pa., Feb. 9 /PRNewswire/ -- Prism Pharmaceuticals announced today that the results of the first-in-man study of PM103, a novel intravenous formulation of clopidogrel bisulfate (the active ingredient in PLAVIX(R)), has been accepted for poster presentation at the 58th Scientific Session of the American College of Cardiology (ACC) on March 29-31, 2009. The poster will be presented at the ACC's Innovation in Intervention: i2 Summit 2009 in partnership with Cardiovascular Research Foundation.

    Presentation Number: 2515-749

    Abstract Title:     Assessment of the pharmacokinetic and pharmacodynamic
                        effects of intravenous clopidogrel in humans

    Time:               Monday, Mar 30, 2009, 9:30 AM -10:30 AM

    Topic:              Pharmacotherapy - Interventional Aspects

    Authors:            Daniel Cushing, Raymond Lipicky, Peter Kowey,
                        Christopher Cannon, Michael Adams, Warren Cooper,
                        Gerold Mosher, Prism Pharmaceuticals

"We are very pleased to present the first data in humans of an IV formulation of clopidogrel at this most prestigious cardiology scientific session," said Dr. Warren D. Cooper, President and CEO of Prism. "PM103 is Prism's second acute care cardiovascular product that is being developed through our accelerated model, which focuses on bringing novel and improved formulations of existing compounds to the market."

About PM103

PM103 is a proprietary, novel intravenous formulation of clopidogrel bisulfate. Clopidogrel is the active ingredient in PLAVIX(R) (clopidogrel bisulfate), an orally available antiplatelet drug marketed by Bristol-Myers Squibb and sanofi-aventis. PM103 is being developed in collaboration with CyDex Pharmaceuticals, Inc. as an alternative dosage form to oral PLAVIX for use in the acute care setting.

About Prism Pharmaceuticals

Prism Pharmaceuticals, based in King of Prussia, Pennsylvania, is a specialty pharmaceutical company committed to developing and commercializing acute care cardiovascular products. The product portfolio strategy is focused on recognizing unfulfilled opportunities in existing compounds that address current unmet medical needs with a specific focus on medication safety in the hospital environment. Recently, Prism received FDA approval for NEXTERONE(R) (amiodarone HCl) Injection, a novel, patent-protected, cosolvent free formulation of the antiarrhythmic agent Amiodarone IV.

For further information, visit

PLAVIX(R) is registered trademarks of sanofi-aventis.

SOURCE Prism Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prism Pharmaceuticals Appoints Maurits Geerlings Vice President of Business Development
2. New Empire BlueCross BlueShield Prism Plans Offer Better Choice and Affordability for New York Small Group Market
3. Prism glasses expand the view for patients with hemianopia
4. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
5. Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Prism Pharmaceuticals to Receive $10 Million Milestone Payment from Paul Capital Healthcare
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
(Date:11/28/2015)... ... , ... Safe storage for contraceptive devices may not always be easy to ... and the other from Bradley Beach, New Jersey, there is an easy solution to ... to replace NuvaRings more often than necessary. As such, it affords peace of mind ...
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing ... last year? , This question has not been an easy question to answer. Especially ... age and the younger workforce don’t share the same discipline around working long hours. ...
(Date:11/27/2015)... ... 27, 2015 , ... The rapid speed at which Americans ... more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming ... The forgotten part of this equation: 80 percent of medical care occurs in ...
(Date:11/27/2015)... ... 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that ... of their purchase of lice treatment product. In addition, customers will receive a complimentary ... spokesperson. “Finding lice is a sure way to ruin the holidays, so we encourage ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
Breaking Medicine Technology: